EyePoint (EYPT) Amortization - Intangibles (2019 - 2022)
EyePoint (EYPT) posted Amortization - Intangibles of $205000.0 for Q4 2022, down 66.67% sequentially from $615000.0 in Q3 2022.
Powered by 
Analysis
EyePoint (EYPT) Amortization - Intangibles (2019 - 2022) Analysis & Trends
EyePoint has reported Amortization - Intangibles for 2 years, with the latest figure at $205000.0 in Q4 2022.
- Quarterly Amortization - Intangibles changed N/A year-over-year to $205000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2023 was $820000.0 (down 42.86% YoY) and the FY2022 annual result came in at $2.0 million, changed N/A from the prior year.
- Amortization - Intangibles retreated to $205000.0 in Q4 2022 per EYPT's latest filing, from $615000.0 in the prior quarter.
- Over five years, Amortization - Intangibles peaked at $615000.0 in Q1 2019 and troughed at $205000.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 205,000.00 |
| Sep 30, 2022 | 615,000.00 |
| Mar 31, 2019 | 615,000.00 |